Receptos to Present at 2013 Credit Suisse Healthcare Conference

Receptos Logo

SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its President and Chief Executive Officer, Faheem Hasnain, will be presenting at the 2013 Credit Suisse Healthcare Conference at the Phoenician Hotel in Scottsdale, AZ. The presentation is scheduled for Tuesday, November 12, 2013, at 1:30 pm Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

CONTACT: Media and Investor Contacts: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708 gcooper@receptos.com Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979 mrice@lifesciadvisors.com

Source:Receptos, Inc.